Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Behavidence Closes $4.3 Million Seed Round to Amplify its Artificial Intelligence Technology used to Detect, Screen and Monitor Mental Illness

Behavidence, a leading startup company that monitors psychiatric and neurological disorders using artificial intelligence, announced a $4.3 million seed round led by Welltech Ventures, featuring Arc Impact and Longevity Ventures.

Founded in 2020 by Roy Cohen (CEO), Dr. Girish Srinivasan, and Dr. Janine Ellenberger, Behavidence tracks and monitors the mental and emotional state of its users based on their digital usage patterns. Through its unique technology and algorithms, Behavidence can delineate the changes in its users’ state of mind without needing identifiable information or monitoring private content or information.

“Today’s funding announcement demonstrates our investors’ support, commitment, and optimism for the future of Behavidence,” said Cohen. “We see Behavidence’s technology being deployed as a screening and remote monitoring tool, and are thrilled to see the adoption of our technology on so many devices across the globe.”

Recommended NewsBuilding Reliable and Secure Fintech Systems in 2022

Behavidence has secured more than $1 million in contracts with customers across the United States, Europe, Africa and Asia. Its clients include the Department of Veterans Affairs, Discovery Health Insurance and Essen Health Care.

Related Posts
1 of 27,858

Behavidence’s product is a remote monitoring tool that helps health organizations, medical practitioners, and insurance companies identify potential diagnoses. According to recent robust clinical studies conducted by Behavidence, the company’s models score up to 80% accuracy in detecting clinical depression, anxiety, and attention deficit disorders (ADHD) in patients. The company is continuing to develop its machine learning-based tools to detect and assist with remote monitoring and management of mental health conditions through passive digital biomarkers, adding no respondent burden.

Recommended AI News: Road Ready Introduces Cloud-Based API Technology and Virtual Tether, Offering Two Unique Solutions That Create a Link Between Truck and Trailer

“We continue to demonstrate our value to large healthcare organizations and private users by helping them assess the mental and emotional state of their clients and customers,” Cohen said. “There is an ease of use to our technology that we are very proud of. The lack of respondent burden for the user makes it easy to implement for both the insurance company and the user. We are seeing metrics from insurance partners that indicate our technology can reduce the cost of a clinical case by up to 50%”

“We are not ruling out the potential of exploring a clinical track either as a medical aid or as the official diagnostic index itself in the future,” explains Cohen. “But for now, we are celebrating our next round of seed funding and focused on delivering an intuitive product that will help serve the mental health needs of individuals and organizations throughout the world.”

Recommended AI News: Tiny Rebel Games Closes $7 Million Round for Petaverse Network, Bringing Furry Family Members to the Metaverse

[To share your insights with us, please write to]

Comments are closed.